News summary

Five-year data show continued benefits of lecanemab in early Alzheimer’s

Source: Longevity Technology • Published: 18 Nov 2026, 13:56

Summarized by Masters of Longevity from Longevity Technology.

Five-year CLARITY-AD extension data report sustained clinical benefit for lecanemab.

Five-year data show continued benefits of lecanemab in early Alzheimer’s
Key Takeaways
  • Lecanemab showed continued clinical benefits over five years.
  • Five-year data suggest treatment effects were maintained long term.
  • Findings are from a long-term extension and are observational.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickNucleotides and Longevity: Is the Evidence Ready?They help build DNA and keep cells working. Early human studies make nucleotide supplements interesting—but leave important questions about healthy ageing unanswered. Yet.MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickSeed Oils and Health: Inflammation, Processing and EvidenceHuman trials, processing risks and long-term health ask different questions. What can seed-oil research tell us—and what remains unresolved?